The potential drawbacks of integration have not received much attention in the past, probably because no adverse effects had been observed in retroviral-mediated gene therapy trials started more than two decades ago (as, for example, in the severe combined immunodeficiency syndrome due to a deficiency in the adenosine deaminase enzyme, SCID-ADA, [183]). The gene discussed is ADA; the disease is combined immunodeficiency syndrome.